RNA Production and Purification Process Development Service
The rapid evolution of messenger RNA (mRNA) as a transformative modality in modern medicine has necessitated a paradigm shift in bioprocessing. Unlike traditional protein-based biologics, RNA molecules are large, highly charged, and inherently sensitive to enzymatic degradation and mechanical shear. Developing a robust production and purification process is the cornerstone of ensuring therapeutic efficacy, safety, and scalability. CD BioGlyco stands at the forefront of this field, offering specialized expertise in the design and optimization of RNA manufacturing workflows.
Our approach integrates advanced chemical engineering principles with molecular biology to address the "bottlenecks" of RNA production, namely, the removal of immunogenic double-stranded RNA (dsRNA) contaminants and the optimization of poly(A) tail integrity. By focusing on high-recovery purification strategies and high-yield enzymatic reactions, we enable our partners to accelerate their developmental timelines while maintaining the highest standards of product purity.
To achieve superior RNA quality, we employ a suite of cutting-edge technologies designed to handle the unique physicochemical properties of long-chain nucleic acids:
Utilizing high-fidelity T7 RNA polymerases and optimized nucleotide feeding strategies to maximize yield while minimizing the formation of truncated variants.
A revolutionary approach that leverages the universal poly(A) tail of mRNA for highly selective capture, increasing resin utilization and throughput compared to traditional batch methods.
Employed for the stringent separation of full-length transcripts from closely related impurities such as dsRNA and DNA templates.
Optimized ultrafiltration and diafiltration (UF/DF) modules that concentrate RNA and facilitate buffer exchange without compromising molecular integrity.
Implementation of digital modeling and statistical design of experiments (DoE) to define the optimal manufacturing design space and ensure process robustness.
The service scope at CD BioGlyco covers the entire developmental journey from initial sequence conceptualization to the finalization of a robust manufacturing protocol. We recognize that each RNA construct, whether it be a standard mRNA, a self-amplifying RNA (saRNA), or a circular RNA, presents unique challenges in stability and secondary structure. Our team provides end-to-end process development that includes plasmid DNA optimization, the selection of high-fidelity polymerases, and the optimization of modified nucleosides to enhance protein expression and reduce immunogenicity.
A significant portion of our service is dedicated to downstream process development (DSP). We focus on eliminating the bottlenecks associated with traditional purification, such as the low productivity of batch chromatography. By implementing continuous processing and multimodal polishing steps, we can reduce the footprint of the manufacturing process while increasing throughput. Our scope includes the development of rigorous analytical methods to measure critical quality attributes (CQAs) like 5' capping efficiency, poly(A) tail length, and residual DNA/protein levels. This holistic approach ensures that the developed process is not only high-yielding but also yields a product with the necessary safety and potency profile for clinical trials. We also offer scale-up studies, transitioning processes from milligram research scales to multi-gram production scales, ensuring that the product quality attributes remain consistent across all stages of development.
We initiate the process with sophisticated mRNA sequence engineering, focusing on 5' and 3' untranslated region (UTR) optimization to enhance stability and translational efficiency, alongside codon optimization to maximize protein expression in the target cell type. The DNA template, typically a plasmid vector, is then linearized using high-fidelity restriction enzymes or PCR-based methods. This is followed by rigorous purification via high-resolution chromatography techniques to ensure complete removal of any nicked, circular, or supercoiled DNA impurities. This foundational step is critical for preventing transcriptional read-through and ensuring the synthesis of a homogeneous mRNA product with precisely defined ends.
The purified linear DNA template serves as the substrate for a highly controlled enzymatic transcription reaction. We systematically fine-tune critical process parameters (CPPs), including magnesium ion concentration, reaction temperature, incubation duration, and the stoichiometric ratios of natural or modified nucleotide triphosphates (NTPs). This precise control over the reaction kinetics and thermodynamics suppresses byproduct formation (such as dsRNA) while driving the reaction toward multi-gram per liter yields of full-length mRNA, ensuring a highly efficient and scalable production process.
The crude IVT mixture is subjected to a selective capture step using oligo-dT affinity chromatography. This technique leverages the complementarity to the poly(A) tail to specifically bind and isolate mature, tailed mRNA transcripts. The process separates the target mRNA from a wide range of process-related impurities, including residual enzymes, short abortive transcripts, free nucleotides, and the DNA template itself. This step not only purifies the product but also serves as an initial quality check, confirming the presence and functionality of the poly(A) tail.
A key purification challenge is the removal of immunogenic double-stranded RNA (dsRNA) byproducts. We address this by employing orthogonal chromatography methods, such as high-resolution anion-exchange (AEX) or hydrophobic interaction chromatography (HIC). These techniques exploit the differential structural and charge characteristics between the desired single-stranded mRNA and dsRNA contaminants. This dedicated purification stage is essential for reducing innate immune response triggers and enhancing the therapeutic safety profile of the final product.
The purified mRNA solution is concentrated and transferred into its final formulation buffer using tangential flow filtration (TFF) with low protein-binding membranes. This step involves a diafiltration process to remove salts and residual solvents from previous steps and replace them with a pharmaceutically acceptable buffer system optimized for stability, storage, or subsequent lipid nanoparticle (LNP) encapsulation. The process is designed to minimize shear stress and maximize product recovery, resulting in a stable, concentrated drug substance ready for downstream applications.
Every final batch undergoes a battery of rigorous analytical tests to confirm identity, purity, potency, and quality. This includes capillary gel electrophoresis (CGE) for accurate integrity and size distribution analysis, reverse-phase HPLC (RP-HPLC) for detailed purity profiling and impurity quantification, and specialized enzymatic or chromatographic assays to determine critical quality attributes like 5' cap addition efficiency and poly(A) tail length homogeneity. This dataset ensures the mRNA product conforms to predefined specifications and supports regulatory submissions.
Journal: Applied Sciences
DOI: 10.3390/app12031543
IF: 2.2
Published: 2022
Results: This review article by Ryczek et al. provides a comprehensive overview of the methodologies available for the large-scale synthesis of RNA, which is critical for structural biology studies using techniques like crystallography, NMR, and cryo-EM that require milligram quantities of homogeneous samples. The authors systematically compare the two primary production strategies: chemical synthesis and in vitro transcription, detailing the principles, advantages, and limitations of each approach. A significant contribution of their work is the presentation of their own experimental results, which directly test and compare the efficiency of these methods for generating different RNA constructs. Their comparative analysis demonstrates that the optimal synthesis strategy is highly dependent on the length and complexity of the desired RNA, leading to practical, data-driven recommendations. Specifically, they outline clear scenarios where chemical synthesis is preferable and contrast them with situations where in vitro transcription proves more effective. Consequently, this paper serves as a valuable guide for researchers, enabling them to select and adapt the most appropriate material acquisition strategy to produce high-quality RNA for their specific structural and functional studies.
Prophylactic Vaccines
Development of high-throughput processes for infectious disease vaccines, enabling rapid response capabilities during pandemic outbreaks or for seasonal flu variants.
Protein Replacement Therapies
Engineering stable mRNA production processes for chronic conditions, focusing on minimizing immunogenicity and maximizing protein expression duration in target tissues.
Antibody-Encoding mRNA
Production of RNA that allows the patient's own cells to produce therapeutic antibodies, bypassing the complexities of traditional recombinant protein manufacturing.
RNA-Based Regenerative Medicine
Creating processes for the production of transcripts that induce tissue repair and regeneration, focusing on biocompatibility and sustained activity.
Absolute Mass Determination
By integrating SEC with MALS technology, we provide the absolute molecular weight of your mRNA constructs, eliminating the inaccuracies associated with relative sizing against potentially mismatched RNA standards.
Rigorous Denaturation Protocols
Our specialized buffers and temperature-controlled separation environments prevent the re-annealing of complex secondary structures, ensuring that every peak in the electropherogram represents a true length variation rather than a conformational artifact.
High-Sensitivity Detection
Our LIF systems allow for the detection of trace-level shortmer impurities that are often invisible to UV-based detectors, providing a more conservative and safer assessment of product purity.
Customizable Analytical Matrices
We offer flexible separation parameters, adjusting voltage, temperature, and buffer concentration to provide the highest possible resolution for your specific mRNA length range, whether it is 1,000 or 12,000 nucleotides.
The process development team at CD BioGlyco transformed our bench-top mRNA synthesis into a highly efficient, scalable protocol. Their expertise in continuous chromatography was a game-changer for our oncology program.
— By Dr. A. Thompson, Principal Scientist, Department of Molecular Medicine
CD BioGlyco provided us with a comprehensive tech transfer package that made our transition to clinical manufacturing seamless. The purity levels they achieved, especially the removal of dsRNA, were outstanding.
— By Manager of Bioprocessing, Vaccines Division
Working with CD BioGlyco felt like having an extension of our own lab. Their collaborative spirit and scientific rigor ensured our mRNA candidate was ready for the clinic on an accelerated timeline.
— By Dr. J. Rivera, Senior Scientist, Rare Disease Research
To provide a holistic therapeutic solution, we offer complementary delivery platforms for advanced molecular types.
Oral Solid Dose Formulation Development Service
Overcoming challenges of RNA stability and permeability in the gastrointestinal tract to develop patient-friendly solid forms like tablets and capsules.
Rectal Dosage Formulation Development Service
Providing a specialized delivery option for local or systemic administration, focusing on formulation and release characteristics specific to this route.
Non-sterile Liquid Dose Formulation Development Service
Developing physically and chemically stable solutions and suspensions for non-invasive routes such as topical or oral delivery.
Sterile Liquid Formulation Development Service
Focusing on the development of sterile, pyrogen-free solution formulations that meet stringent requirements for injectable routes like intravenous.
Lyophilized Drug Formulation Development Service
Addressing long-term RNA stability challenges by developing lyophilized powders, where excipients protect the RNA molecule in a solid state, facilitating storage and transport.
CD BioGlyco is dedicated to empowering the next generation of RNA medicine. By providing world-class process development and purification expertise, we help our clients navigate the complexities of RNA manufacturing with confidence. Our commitment to quality, scalability, and scientific innovation ensures that your therapeutic vision can become a clinical reality. Contact us!
Reference
